Keyphrases
Health Technology Assessment
100%
European Union
39%
Confidence Interval
38%
Netherlands
33%
Europe
27%
Direct Oral Anticoagulants
27%
Uganda
23%
Atrial Fibrillation
23%
European Medicines Agency
22%
United States
19%
Assessment Agency
19%
Gene Therapy
18%
Access to Medicines
18%
Population-based Cohort Study
18%
Type 2 Diabetes Mellitus (T2DM)
18%
Non-vitamin K Antagonist Oral Anticoagulants
17%
Reimbursement
17%
Kenya
17%
Marketing Authorization
17%
Medicinal Products
17%
Major Bleeding
16%
Relative Effectiveness Assessment
16%
European Countries
16%
Drug Development
15%
Vitamin K Antagonists
15%
Dutch
14%
Healthcare Professionals
14%
Health Systems
14%
Essential Medicines
14%
Managed Entry Agreements
13%
Advanced Therapy Medicinal Products
13%
Non-valvular Atrial Fibrillation
13%
Zambia
13%
Biosimilar
13%
Decision Maker
12%
Cell-based
12%
Drug Utilization Study
11%
Adverse Events
11%
Primary Care
11%
Health Technology
11%
VigiBase
11%
Low-middle Income Countries
11%
Hazard Ratio
11%
Post-approval Changes
11%
Payment Method
11%
Meta-analysis
11%
Oral Anticoagulants
11%
Lessons Learned
11%
Retrospective Cohort Study
10%
International Society
10%
Antibiotics
10%
Canada
10%
Denmark
10%
Oncology
10%
Dabigatran
10%
Apixaban
10%
Comparative Effectiveness
9%
Regulatory Technology
9%
Unmet Medical Need
9%
Adverse Drug Reaction
9%
Pharmacoepidemiology
9%
Postmarketing
9%
Rivaroxaban
9%
Inception Cohort Study
9%
Medicines for children
9%
COVID-19
9%
Reimbursement Mechanisms
9%
Central and Eastern European Countries
9%
Summary of Product Characteristics (SmPC)
9%
Public Health
9%
Clinical Practice Research Datalink
9%
Ghana
9%
Outcomes Research
9%
Multi-stakeholder
9%
Pharmacy
8%
National Essential Medicine List
8%
Health Decision-making
8%
Quality of Life
8%
Incidence Rate
8%
Real-world Evidence Study
8%
South Africa
8%
Systematic Meta-analysis
8%
European Public Assessment Report
8%
Orphan Drugs
8%
Spain
8%
Multiple Sclerosis
8%
Pharmacist
8%
Assessment Practices
8%
Health-related Quality of Life
8%
Pharmaceutical Companies
7%
Drug Safety
7%
Payers
7%
Stakeholder Survey
7%
Prescribers
7%
Pharmacovigilance
7%
Cystic Fibrosis
7%
Politicians
7%
Reimbursement Models
7%
Quality Assessment
7%
Regulatory Agencies
7%
Medicine and Dentistry
Medicine
63%
Health Technology
55%
Technology Assessment
50%
Cohort Analysis
28%
Decision Making
23%
Assessment in Health Technology
23%
Atrial Fibrillation
22%
Antithrombotic
20%
Vitamin K Antagonist
19%
Health Care Cost
17%
Essential Medicines
16%
Public Health
16%
Diseases
15%
Oncology
14%
Quality of Life
13%
Diabetes
13%
Health Care
13%
Systematic Review
12%
Health System
12%
Apoplexy
11%
Maturity Onset Diabetes of the Young
11%
Advanced Therapy
11%
Biosimilar
11%
Malignant Neoplasm
10%
Major Bleeding
10%
Hazard Ratio
10%
Adverse Event
10%
Primary Health Care
10%
Cost-Effectiveness Analysis
10%
Direct Oral Anticoagulant
9%
Breast Cancer
8%
Health Outcomes
8%
Gene Therapy
7%
TNF Inhibitor
7%
Observational Study
7%
Adverse Drug Reaction
7%
COVID-19
7%
Meta-Analysis
7%
Melanoma
6%
Low and Middle Income Countries
6%
Awareness
6%
Cross Sectional Study
6%
Cancer Risk
6%
Prevalence
6%
Orphan
6%
Combination Therapy
6%
Cell Therapy
6%
Electronic Health Record
5%
Patient Population
5%
Clinical Research
5%
Reproductive Public Health
5%
Hodgkin's Lymphoma
5%
Childhood Cancer
5%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
Retrospective Cohort Study
5%
Pharmacovigilance
5%
Randomized Controlled Trial
5%
Pediatrics
5%